Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study

Background The choice of an optimal oral hypoglycemic agent in the initial treatment periods for type 2 diabetes mellitus (T2DM) patients remains difficult and deliberate. We compared the efficacy and safety of glimepiride (GLIM), alogliptin (ALO), and alogliptin-pioglitazone (ALO-PIO) in poorly con...

Descripció completa

Dades bibliogràfiques

Autors principals:	Hae Jin Kim, In Kyung Jeong, Kyu Yeon Hur, Soo-Kyung Kim, Jung Hyun Noh, Sung Wan Chun, Eun Seok Kang, Eun-Jung Rhee, Sung Hee Choi
Format:	Artigo
Idioma:	Inglês
Publicat:	Korean Diabetes Association 2022-09-01
Col·lecció:	Diabetes & Metabolism Journal
Matèries:	alogliptin diabetes mellitus, type 2 glimepiride glycemic control pioglitazone
Accés en línia:	http://e-dmj.org/upload/pdf/dmj-2021-0183.pdf
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!